This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

This study has been completed.
Serenex, Inc.
Information provided by:
Esanex Inc. Identifier:
First received: January 7, 2008
Last updated: May 15, 2012
Last verified: May 2012
Hsp90 is a chemical in the body that is involved in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Condition Intervention Phase
Hematologic Neoplasms Drug: SNX-5422 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

Further study details as provided by Esanex Inc.:

Primary Outcome Measures:
  • adverse events and other safety assessments [ Time Frame: continuous ]

Secondary Outcome Measures:
  • disease response specific to the hematological malignancy [ Time Frame: after every 2 cycles ]

Enrollment: 25
Study Start Date: January 2008
Study Completion Date: May 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single Arm Drug: SNX-5422
dose escalated; tablets every other day; undetermined duration until disease progression


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • >18 years old
  • Karnofsky performance status > 60
  • confirmed hematological malignancy
  • refractory to available therapy or for which no therapy is available
  • adequate hepatic, renal and hematological function

Exclusion Criteria:

  • CNS malignancy
  • at risk for prolonged QT interval
  • significant GI/liver disease
  • other serious concurrent illness or medical condition
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00595686

United States, Georgia
Pfizer Investigational Site
Augusta, Georgia, United States, 30912
United States, North Carolina
Pfizer Investigational Site
Chapel Hill, North Carolina, United States, 27599
United States, Pennsylvania
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States, 15232
United States, Tennessee
Pfizer Investigational Site
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Esanex Inc.
Serenex, Inc.
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT00595686     History of Changes
Other Study ID Numbers: B1311002
Study First Received: January 7, 2008
Last Updated: May 15, 2012

Keywords provided by Esanex Inc.:
Hematologic Malignancies Hsp90 Hematologic Malignancy

Additional relevant MeSH terms:
Hematologic Neoplasms
Neoplasms by Site
Hematologic Diseases processed this record on September 21, 2017